Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the analyst consensus estimate of $(2.85) by 51.23 percent. This is a 25.69 percent increase over losses of $(5.80) per share from the same period last year. The company reported quarterly sales of $26.000 thousand which missed the analyst consensus estimate of $1.500 million by 98.27 percent. This is a 97.87 percent decrease over sales of $1.222 million the same period last year.